Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952426 · ClinicalTrials.gov registry record
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
A clinical trial of Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06952426: Recruiting study of Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals.
NCT06952426 is a study of Immunoglobulin A Nephropathy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 300 participants, roughly in line with the 281-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06952426, a study of Immunoglobulin A Nephropathy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
Primary Outcome
To assess and gain a comprehensive understanding of the patient-reported burden of Immunoglobulin A nephropathy (IgAN) using home-reported outcome (HRO) symptom tracking data. Patients will select from a list of suggested symptoms. The 10 symptoms most frequently reported will be presented and analyzed.
Conditions Studied
Interventions
- OTHER No intervention
- OTHER Other treatment
- OTHER Iptacopan
- OTHER Atrasentan
Study Locations (1)
Massachusetts
- Novartis Investigational site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2025-06-30 |
What NCT06952426 shows while recruiting
NCT06952426 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 281-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target.
The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 4 interventions - of which No intervention is the first listed.
NCT06952426 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06952426 about?
NCT06952426 is a clinical study titled "A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
What is the current status of trial NCT06952426?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-03-04. Estimated completion is 2025-06-30.
What conditions does trial NCT06952426 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.
What interventions are being tested in trial NCT06952426?
The interventions under investigation include: No intervention (OTHER), Other treatment (OTHER), Iptacopan (OTHER), Atrasentan (OTHER).
Who is sponsoring clinical trial NCT06952426?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952426 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06952426's enrollment target sits among peer trials
300 8th of 13 higher than 6 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
RECRUITING · Phase 2
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI